Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Hyperfine (HYPR) Total Liabilities (2020 - 2026)

Hyperfine filings provide 7 years of Total Liabilities readings, the most recent being $26.0 million for Q1 2026.

  • On a quarterly basis, Total Liabilities rose 153.12% to $26.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $26.0 million, a 153.12% increase, with the full-year FY2025 number at $14.3 million, up 44.58% from a year prior.
  • Total Liabilities hit $26.0 million in Q1 2026 for Hyperfine, up from $14.3 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $26.0 million in Q1 2026 to a low of $9.3 million in Q3 2023.
  • Median Total Liabilities over the past 5 years was $10.3 million (2025), compared with a mean of $11.8 million.
  • Biggest five-year swings in Total Liabilities: tumbled 36.42% in 2022 and later soared 153.12% in 2026.
  • Hyperfine's Total Liabilities stood at $10.3 million in 2022, then decreased by 5.12% to $9.8 million in 2023, then rose by 0.62% to $9.9 million in 2024, then skyrocketed by 44.58% to $14.3 million in 2025, then skyrocketed by 82.21% to $26.0 million in 2026.
  • The last three reported values for Total Liabilities were $26.0 million (Q1 2026), $14.3 million (Q4 2025), and $14.6 million (Q3 2025) per Business Quant data.